Literature DB >> 24412248

Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis.

Barry B Mook-Kanamori1, Matthijs C Brouwer1, Madelijn Geldhoff1, Arie van der Ende2, Diederik van de Beek3.   

Abstract

BACKGROUND: Recent research into the treatment of bacterial meningitis has examined the innate immune system, specifically the complement system, as a potential target for adjuvant therapy. However, the effects of blocking the complement system may be pathogen dependent.
METHODS: We measured cerebrospinal fluid (CSF) levels of complement components C1q, C3a, iC3b, C5a, sC5b-9, CFH and MBL in 310 patients with pneumococcal and meningococcal meningitis from a prospective nationwide cohort study. The CSF complement component levels were successfully determined for between 289 (93%) and 307 (99%) patients, depending on available volumes of stored CSF.
RESULTS: Complement factors C1q and MBL as well as common complement pathway factors C3a, iC3b, C5a, sC5b-9 and complement regulator CFH were all elevated in patients with bacterial meningitis as compared to the controls. CSF levels of complement components C5a and sC5b-9 were higher in patients with pneumococcal meningitis compared to those with meningococcal meningitis. After correction for age, immunocompromised state and level of consciousness, the CSF concentrations of C5a and sC5b-9 remained different between causative microorganisms (P = 0.006 and P = 0.016 respectively). In pneumococcal meningitis high C5a and C5b-9 levels are associated with the occurrence of systemic complications, unfavorable outcome and death, whereas an inverse relationship between C5b-9 levels and mortality is observed in meningococcal meningitis.
CONCLUSIONS: Our study shows striking variations in complement activation depending on the pathogen responsible for the bacterial meningitis. In pneumococcal meningitis, high CSF complement levels were a strong indicator of disease severity and mortality, however in meningococcal meningitis, an inverse relationship between sC5b-9 and mortality was observed.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Bacterial meningitis; Complement system; Therapy

Mesh:

Substances:

Year:  2014        PMID: 24412248     DOI: 10.1016/j.jinf.2013.12.016

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

1.  Quantification of Complement Proteins with Special Reference to C1q: Multiplex Versus ELISA Versus Rocket Immunoelectrophoresis Versus Nephelometry.

Authors:  Kerstin Sandholm; Barbro Persson; Sliva Abdalla; Camilla Mohlin; Bo Nilsson; Kristina N Ekdahl
Journal:  Methods Mol Biol       Date:  2021

2.  Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with long-standing nodding syndrome: A case-control study.

Authors:  Rodney Ogwang; Dennis Muhanguzi; Kioko Mwikali; Ronald Anguzu; Joe Kubofcik; Thomas B Nutman; Mark Taylor; Charles R Newton; Angela Vincent; Andrea L Conroy; Kevin Marsh; Richard Idro
Journal:  Epilepsia Open       Date:  2021-03-12

3.  Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial.

Authors:  E Soemirien Kasanmoentalib; Mercedes Valls Seron; B Paul Morgan; Matthijs C Brouwer; Diederik van de Beek
Journal:  J Neuroinflammation       Date:  2015-08-15       Impact factor: 8.322

4.  Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis.

Authors:  E Soemirien Kasanmoentalib; Mercedes Valls Seron; Bart Ferwerda; Michael W Tanck; Aeilko H Zwinderman; Frank Baas; Arie van der Ende; William J Schwaeble; Matthijs C Brouwer; Diederik van de Beek
Journal:  J Neuroinflammation       Date:  2017-01-03       Impact factor: 8.322

5.  Increased activity of the complement system in cerebrospinal fluid of the patients with Non-HIV Cryptococcal meningitis.

Authors:  Lei Shen; Jianming Zheng; Yan Wang; Mengqi Zhu; Haoxiang Zhu; Qi Cheng; Qian Li
Journal:  BMC Infect Dis       Date:  2017-01-04       Impact factor: 3.090

6.  Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment.

Authors:  Johannes B Herrmann; Marcel Muenstermann; Lea Strobel; Alexandra Schubert-Unkmeir; Trent M Woodruff; Scott D Gray-Owen; Andreas Klos; Kay O Johswich
Journal:  mBio       Date:  2018-01-23       Impact factor: 7.867

7.  Intrathecal complement activation by the classical pathway in tick-borne encephalitis.

Authors:  Malin Veje; Marie Studahl; Tomas Bergström
Journal:  J Neurovirol       Date:  2019-03-08       Impact factor: 2.643

8.  Evaluation of a Novel Immunoassay for Quantification of C1q for Clinical Diagnostic Use.

Authors:  Kerstin Sandholm; Barbro Persson; Lillemor Skattum; Gösta Eggertsen; Dag Nyman; Iva Gunnarsson; Elisabet Svenungson; Bo Nilsson; Kristina N Ekdahl
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

Review 9.  Targeting the complement system in bacterial meningitis.

Authors:  Diederik L H Koelman; Matthijs C Brouwer; Diederik van de Beek
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

10.  Complement factor H contributes to mortality in humans and mice with bacterial meningitis.

Authors:  E Soemirien Kasanmoentalib; Mercedes Valls Serón; Joo Yeon Engelen-Lee; Michael W Tanck; Richard B Pouw; Gerard van Mierlo; Diana Wouters; Matthew C Pickering; Arie van der Ende; Taco W Kuijpers; Matthijs C Brouwer; Diederik van de Beek
Journal:  J Neuroinflammation       Date:  2019-12-28       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.